DCTH · Delcath Systems
AI read · Good for DCTH
The AI's read
More treatment centers and a steady flow of new patients give Delcath more room to grow sales. The company says current sales are funding work on other cancers where the liver is a main site. One caution is its expected 2026 gross profit margin of 86% to 89%, below Q2's 90%. The higher sales forecast and expanding treatment network point to a stronger business outlook.